Anti-Coagulants - Benelux

Benelux

In the Anti-Coagulants market, the projected revenue for Benelux is expected to reach US$353.10m in 2024.
Looking ahead, there is an anticipated annual growth rate (CAGR 2024-2029) of 7.17%, which would result in a market volume of US$499.10m by 2029.
When compared globally, United States is expected to generate the highest revenue, with US$16,740.00m projected for 2024.
The demand for anti-coagulants in the Benelux market is steadily increasing due to the aging population and rising prevalence of cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Benelux has been steadily growing over the years.

Customer preferences: Patients in Benelux are increasingly preferring oral anticoagulants over traditional injectable ones due to their ease of use and fewer side effects. Additionally, there is a growing trend towards personalized medicine, where patients are prescribed anticoagulants based on their genetic makeup and medical history.

Trends in the market: There has been a shift towards direct oral anticoagulants (DOACs) in the Benelux market, which are more convenient for patients and have a lower risk of causing bleeding. This has led to a decline in the use of traditional anticoagulants such as warfarin. The market for DOACs is expected to continue to grow in the coming years due to their increasing popularity among patients and their effectiveness in preventing blood clots.

Local special circumstances: The Benelux region has a high prevalence of atrial fibrillation, which is a major risk factor for stroke. This has led to an increase in the demand for anticoagulants in the region. Additionally, the aging population in Benelux has contributed to the growth of the anticoagulants market as older adults are more likely to develop conditions that require anticoagulation therapy.

Underlying macroeconomic factors: The healthcare sector in Benelux is highly developed and well-funded, which has contributed to the growth of the anticoagulants market. Additionally, the region has a strong pharmaceutical industry with several major players in the anticoagulants market. The favorable regulatory environment in Benelux has also played a role in the growth of the market, with the government providing support for the development and approval of new anticoagulant drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.